New research reveals that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Published data in a leading health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying these medications need to be cognizant of the risk of fast rebound weight gain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment mass within about a year and a half.
Analyzing Approaches
The study, which reviewed dozens of trials involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods.
The team note that people who shed pounds through diet and exercise generally experience a less rapid creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Rapid Rebound
Experts propose the mechanism of the drugs is key to understanding the accelerated weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal may cause the body to produce less of its own natural hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means appetite is uncontrolled, making binge eating a significant risk."
An Ongoing Disease?
The NHS recommend the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the significant potential of relapse, the therapy should be considered ongoing.
This opinion is supported by drug manufacturers, who state that the findings "emphasize the long-term nature of obesity," comparing it to managing conditions like hypertension.
User Experiences
Individuals who have discontinued the jabs describe a intense return of hunger.
"I experienced a trigger flipping and I was suddenly ravenous," described a patient.
This difficulty is worsened if patients have not developed sustainable lifestyle or habit changes during treatment.
Widespread Adoption
Recent estimates suggest that millions of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is higher among females compared to males.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, experts emphasize that while these medications are effective agents for weight loss, they are not a standalone fix and lasting health benefits likely depends on combined lifestyle support.
